We are live on ! Find out more
LFCR icon

Lifecore Biomedical
LFCR

Fund managers haven’t disclosed any holdings of LFCR yet.

LFCR Hedge Fund Activity: Q1 2026 in Review

105 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2026, worth a combined $112M — down 50% from $226M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LFCR positions and 17 closed out — a net gain of 3 holders — while 30 added to existing stakes and 33 trimmed.

The largest buyer was Wittenberg Investment Management, adding an estimated $1.93M. The largest seller was Greenhaven Road Investment Management, cutting an estimated $1M.

  • 105 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2026, up from 103 in Q4 2025.
  • Funds reported $112M of Lifecore Biomedical stock for Q1 2026, down 50% quarter-over-quarter.
  • 20 funds opened new Lifecore Biomedical positions in Q1 2026 and 17 closed out, a net change of +3 holders.
  • The largest Lifecore Biomedical buyer in Q1 2026 was Wittenberg Investment Management, an estimated $1.93M added.
  • The largest Lifecore Biomedical seller in Q1 2026 was Greenhaven Road Investment Management, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2026.